Cancer is a major burden of disease globally. Each year, tens of millions of people are
diagnosed with cancer worldwide, and more than half of the patients eventually die from it …

The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free
remission (TFR; ie, the ability to maintain a molecular response after stopping therapy) …

The dramatic success of tyrosine kinase inhibitors (TKIs) has led to the widespread
perception that chronic myeloid leukemia (CML) has become another chronic disease …

Abstract Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic
phase (CML-CP) is considered a feasible option, especially with the ability of second …

Background Discontinuation of tyrosine kinase inhibitor (TKI) therapy is feasible for some
patients with chronic myeloid leukaemia with deep molecular responses; however, patients …

Background: We analyzed the cost-effectiveness of treating incident chronic myeloid
leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in …

The main objective of this study was to compare the reporting of health status and symptom
severity, for a set of core symptoms related to imatinib therapy, between chronic myeloid …

Leukemia comprises a group of hematological malignancies responsible for 8% of all
cancers and is the most common cancer in children. Despite significant improvements in …

Abstract Heat shock protein 90 (HSP90) stabilizes many client proteins, including the BCR-
ABL1 oncoprotein. BCR-ABL1 is the hallmark of chronic myeloid leukemia (CML) in which …